Editorial Comment on: External Validation of the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear-Cell Renal Cell Carcinoma in a Single European Centre Applying Routine Pathology

被引：3
作者：
Blute, Michael L. [1 ]
机构：
[1] Mayo Clin, Dept Urol, Rochester, MN 55905 USA
来源：
EUROPEAN UROLOGY | 2010年 / 57卷 / 01期
关键词：
D O I：
10.1016/j.eururo.2008.11.035
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：110 / 111
页数：2
相关论文
共 3 条
[1]   Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].
Hudes, Gary ;
Carducci, Michael ;
Tomczak, Piotr ;
Dutcher, Janice ;
Figlin, Robert ;
Kapoor, Anil ;
Staroslawska, Elzbieta ;
Sosman, Jeffrey ;
McDermott, David ;
Bodrogi, Istvan ;
Kovacevic, Zoran ;
Lesovoy, Vladimir ;
Schmidt-Wolf, Ingo G. H. ;
Barbarash, Olga ;
Gokmen, Erhan ;
O'Toole, Timothy ;
Lustgarten, Stephanie ;
Moore, Laurence ;
Motzer, Robert J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281
[2]  
PANTUCK AJ, 2007, CANCER, V5, P379
[3]   External Validation of the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear-Cell Renal Cell Carcinoma in a Single European Centre Applying Routine Pathology [J].
Zigeuner, Richard ;
Hutterer, Georg ;
Chromecki, Thomas ;
Imamovic, Arvin ;
Kampel-Kettner, Karin ;
Rehak, Peter ;
Langner, Cord ;
Pummer, Karl .
EUROPEAN UROLOGY, 2010, 57 (01) :102-109
1